EP4673542A1 - Plac8 antisense molecules used as a medicament - Google Patents

Plac8 antisense molecules used as a medicament

Info

Publication number
EP4673542A1
EP4673542A1 EP24706690.5A EP24706690A EP4673542A1 EP 4673542 A1 EP4673542 A1 EP 4673542A1 EP 24706690 A EP24706690 A EP 24706690A EP 4673542 A1 EP4673542 A1 EP 4673542A1
Authority
EP
European Patent Office
Prior art keywords
plac8
antisense molecule
molecule according
overexpression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24706690.5A
Other languages
German (de)
French (fr)
Inventor
Thomas M. GRESS
Malte Buchholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philipps Universitaet Marburg
Original Assignee
Philipps Universitaet Marburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philipps Universitaet Marburg filed Critical Philipps Universitaet Marburg
Publication of EP4673542A1 publication Critical patent/EP4673542A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Definitions

  • the present invention relates to antisense molecules for use as a medicament , in particular the use of these antisense molecules for the treatment of diseases associated with the overexpression of PLAC8 , a method for treating disease associated with overexpression of PLAC8 and a kit containing these antisense molecules .
  • the antisense- mediated degradation of nuclear PLAC8 mRNA is described as a novel therapeutic approach for the treatment of mainly pancreatic malignancies . It has been found that pancreatic cancer cells are addicted to expression of the PLAC8 mRNA, but not the encoded protein, for maintenance of genome integrity and cell viability
  • pancreas pancreatic ductal adenocarcinoma ; PDAC
  • PDAC pancreatic ductal adenocarcinoma
  • chemotherapeutic approaches have predominantly been used, which unspeci f ically target rapidly proli ferating cells . Since this also af fects numerous normal cells within the body, such therapies are usually associated with severe undesired side ef fects .
  • Molecular-targeted therapies that speci fically address molecular changes in tumor cells and are therefore less harmful to healthy body cells have not yet been success fully established for PDAC therapy .
  • Another novel concept are so- called immune checkpoint inhibitor therapies , which have already shown impressive success in other tumor entities . They aim to inhibit mechanisms by which tumor cells protect themselves from attack by the body ' s own immune system .
  • These therapies have also proven largely inef fective in PDAC to date , but can presumably be rendered ef fective by generating DNA damage in tumor cells , since this dramatically increases the number of immune-stimulatory signals .
  • the technical problem underlying the present invention is to provide means for treating diseases associated with the overexpression of the protein PLAC8 avoiding the problems of the prior art approaches .
  • the present invention provides an antisense molecule binding to the mRNA of the protein PLAC8 for use as a medicament .
  • Antisense oligonucleotides are synthetic, short-chain, single-stranded nucleic acids that are made up of a few nucleotides ( typically from 15 up to 30 nucleotides ) from a freely selectable sequence of bases .
  • ASOs bind via complementary base pairing to a nucleic acid whose base sequence matches them ( opposite base pairs - " anti-sense” ) .
  • the antisense molecule is used for the treatment of diseases associated with an overexpression of PLAC8, for example cancer, like a pancreatic tumor, acute myeloide leukemia (AML) , cervical cancer, glioblastoma or renal clear cell carcinoma.
  • the pancreatic tumor can be a pancreatic ductal adenocarcinoma (PDAC) or a pancreatic neuroendocrine tumor (PanNET) .
  • the antisense molecule is an antisense oligonucleotide, which can have from 15 up to 30 nucleotides, in particular 15 to 20 nucleotides.
  • the antisense molecule can be selected from the group consisting of siRNA, shRNA and GapmeRs .
  • GapmeRs contain a central DNA region flanked on both sides with RNA regions. That is, the GapmeR can be represented in a simplified formula as RNA-DNA-RNA. That is, GapmeRs are DNA antisense structures with RNA-like segments on both sides of the sequence. These linear pieces of genetic information are designed to hybridize to a target piece of RNA (in the present case PLAC8) and silence the gene through the induction of cleavage. Binding of the GapmeRs to the target can have higher affinity due to modified RNA flanking regions, as well as resistance to degradation by nucleases.
  • the RNA regions can be chemically modified.
  • the chemical modification can be selected from the group consisting of 2'-0Me modified bases or 2'-F modified bases or a methylene bridge between the 2'-0 and the 4'-C-atom.
  • GapmeRs having such a chemical modification of the RNA regions are known as LNA GapmeRs (LNA means locked nucleic acids) , wherein the RNA is locked in an ideal Watson-Crick pairing conformation due to the locking provided by the chemical modification.
  • Antisense molecules used according to the present invention are known to the skilled person so that materials and methods for producing them are available . Furthermore , such antisense molecules are commercially available .
  • LNA Gampers can be purchased from Qiagen .
  • the antisense molecule can be used together with a so-called immune checkpoint inhibitor .
  • This use can be carried out in that the checkpoint inhibitor is delivered before , together with or after the delivery of the antisense molecule .
  • the antisense molecule as defined above for treating a disease associated with overexpression of PLAC8 as defined above as well .
  • a further subj ect-matter of the present invention is a method for treating a disease associated with overexpression of PLAC8 with an antisense molecule .
  • a disease associated with overexpression of PLAC8 with an antisense molecule .
  • the antisense molecule and the diseases it is referred to the above detailed description in its entirety .
  • the present invention relates to a kit containing an antisense molecule directed against the mRNA of PLAC8 and instructions for use for treating a disease associated with PLAC8 overexpression .
  • the kit further contains an immune checkpoint inhibitor .
  • PLAC8 is a gene encoding a small protein with unknown function .
  • PLAC8 is practically absent in normal pancreatic tissue , but is regularly found highly overexpressed in PDAC as well as in other tumors . It has previously been shown that the PLAC8 gene , which codes for an evolutionarily highly conserved small protein of 115 AA, is strongly ectopically expressed in pancreatic ductal adenocarcinoma ( PDAC ) as well as a subset of pancreatic neuroendocrine tumors ( PanNET ) . Inhibition of PLAC8 expression signi ficantly impairs cell proli feration and viability in PDAC and PanNET cells .
  • the functional entity mediating the cell-intrinsic pro-tumorigenic ef fects is not the PLAC8 protein, but the PLAC8 mRNA itsel f .
  • the functional entity mediating the cell-intrinsic pro-tumorigenic ef fects is not the PLAC8 protein, but the PLAC8 mRNA itsel f .
  • the mRNA itsel f that is critical for tumor cell survival and proli feration, speci fically in a function within the nucleus itsel f (by default , mRNAs are transported out of the nucleus and translated into protein at ribosomes ) .
  • LNA GapmeRs Using commercially available antisense molecules ( ' LNA GapmeRs ' ; purchased from Qiagen GmbH) , it has been shown that targeted degradation of PLAC8 mRNA in the nucleus leads to massive DNA damage in the cell and, as a consequence , to complete inhibition of proli feration and ultimately cell death . Since LNA GapmeRs are in parts chemically modi fied DNA molecules , they are protected from degradation in the organism and can therefore also be used in vi vo .
  • Figure 1 shows data about PLAC8.
  • FIG. 1 shows the CRISPR/Cas9 targeting of PLAC8.
  • Figure 3 shows the genotype of S2-007-derived clone G2#l.
  • Figure 4 shows the pedigree of S2-007-derived clones.
  • Figure 5 shows the genomic organization and splice variants.
  • Figure 6 shows principles of function of the LNA-GapmeRs .
  • Figure 7 shows the GapmeRs effects in G2#l clone.
  • the gene is located on chromosome 4 with 3-4 alleles per cell (S2 — 007 cell line) .
  • the gene codes for a small protein (18 kDa) highly conserved in evolution. It is overexpressed in PDAC, which leads to enhanced cell proliferation so that it can be considered to be an oncogene.
  • S2-007 clones with targeted inactivation of PLAC8 expression were generated using the CRISPR/Cas9 technology.
  • the successful inactivation of all alleles should have abrogated protein and RNA expression completely (integration of an antibiotics resistance/ transcription stop cassette) .
  • Clones devoid of PLAC8 protein were readily obtained, but grew as well as parental cells, and still reacted to PLAC8-specif ic siRNA transfection.
  • the S2-007 clone is deprived of PLAC8 protein expression generated using the CRISPR/Cas9 technology.
  • the usage of guide RNA 2 Clone G2#l was chosen for the CRISPR/Cas9 approach described in the following as this clone already had 2-3 incorporated transcription-stop cassettes at the PLAC8 gene locus and only one remaining "wt"-allele (with a frameshift caused by NHEJ) , which results in cells lacking the PLAC8 protein, but not the PLAC8 RNA.
  • the Clone G2#l derives from the S2-007 cell line and was created via a first round of CRISPR/Cas9 editing using a donor plasmid coding for a puromycin transcription-stop cassette.
  • genotype of clone G2#l it is already known that this clone has 3 integrated puromycin transcription-stop cassettes and 1 allele with a frameshift (4 NT-deletion) within exon 2 at the PLAC8 gene locus. This results in a gene KO at the protein, but not at the RNA level.
  • Fig. 4 shows the pedigree of S2-007-derived clones.
  • the second round only yielded clones with additional indels, but not a single clone without RNA expression.
  • LNA-GapmeRs The principle of function of LNA-GapmeRs is represented in Fig. 6.
  • GapmeR's in general have at least one of the following properties: They are antisense oligonucleotides (ASO, they are short (15-20 bases) single stranded nucleic acids. They have a central DNA "gap” (central DNA part) flanked by RNA pars on each side. They form DNA: RNA duplexes detected by RNaseH. Flanking regions contain " locked nucleic acids” ( LNA) which are nuclease resistant and have enhanced binding .
  • ASO antisense oligonucleotides
  • LNA locked nucleic acids
  • Fig . 7 shows individual/ independent GapmeRs elicited ef ficient knockdown of both, PLAC8 protein ( in parental cells ) and PLAC8 mRNA ( in PLAC8 protein-proficient as well as protein-deficient cell lines/clones ) .
  • PLAC8 knockdown led to profound growth inhibition regardless of protein status , far surpassing ef ficacy of siRNAs .
  • Fig . 8 it represents flow cytometry ( PI staining) showing slightly pronounced S-Phase , but BrdU assays demonstrated that cell proli feration was severely impaired after PLAC8 knockdown . Moreover, gamma-H2AX staining revealed induction on massive amounts of cell death, peaking 24h after trans fection of GapmeRs .
  • PLAC8 protein-deficient clones showed no di f ferences in growth rates compared to parental cell lines , but strongly reacted to PLAC8 mRNA knockdown, in particular to LNA GapmeR-mediated knockdown of nuclear-located PLAC8 mRNA, with induction of massive DNA damage and growth inhibition .
  • Nanopore sequencing identi fied several novel PLAC8 splice isoforms , but recombinant expression of none of these isoforms was able to rescue the knockdown phenotype .
  • PLAC8 mRNA i functions similarly to a cis-acting long non-coding RNA; ii ) has an important and non-redundant role in maintaining genomic integrity in pancreas cancer cells ; and ill ) functions completely independently of the encoded protein . Both aspects ( separate functions of mRNA and encoded protein, and a central role of an mRNA in maintaining genome stability) have not previously been described in any cellular context .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to an antisense molecule binding to the mRNA of the protein PLAC8 for use as a medicament, for example for the treatment of cancer, in particular pancreatic ductal adenocarcinoma. Furthermore, the use of such antisense molecules and a method for treating of cancer as well as a kit containing the antisense molecules are described.

Description

PLAC8 Antisense Molecules Used as a Medicament
The present invention relates to antisense molecules for use as a medicament , in particular the use of these antisense molecules for the treatment of diseases associated with the overexpression of PLAC8 , a method for treating disease associated with overexpression of PLAC8 and a kit containing these antisense molecules . In the following the antisense- mediated degradation of nuclear PLAC8 mRNA is described as a novel therapeutic approach for the treatment of mainly pancreatic malignancies . It has been found that pancreatic cancer cells are addicted to expression of the PLAC8 mRNA, but not the encoded protein, for maintenance of genome integrity and cell viability
Malignant tumors of the pancreas (pancreatic ductal adenocarcinoma ; PDAC ) are extremely aggressive and presently incurable . Currently, available treatment options have very limited ef ficacy and are usually associated with severe side ef fects .
Overexpression of the PLAC8 gene in pancreatic tumors has been reported several times in the literature . Proli feration inhibition of pancreatic cancer cells in vi tro ( i . e . , in cell culture ) after downregulation of PLAC8 expression has also been described; however, other techniques were used in these cases that did not speci fically target nuclear mRNA; the ef fects observed should be improved; and speci fically, the ef fect on chromosome stability was not observable in these previous studies .
In the treatment of pancreatic cancer, chemotherapeutic approaches have predominantly been used, which unspeci f ically target rapidly proli ferating cells . Since this also af fects numerous normal cells within the body, such therapies are usually associated with severe undesired side ef fects . Molecular-targeted therapies that speci fically address molecular changes in tumor cells and are therefore less harmful to healthy body cells have not yet been success fully established for PDAC therapy . Another novel concept are so- called immune checkpoint inhibitor therapies , which have already shown impressive success in other tumor entities . They aim to inhibit mechanisms by which tumor cells protect themselves from attack by the body ' s own immune system . These therapies have also proven largely inef fective in PDAC to date , but can presumably be rendered ef fective by generating DNA damage in tumor cells , since this dramatically increases the number of immune-stimulatory signals .
The technical problem underlying the present invention is to provide means for treating diseases associated with the overexpression of the protein PLAC8 avoiding the problems of the prior art approaches .
This has been solved by the subj ect-matter of the independent claims . Preferred embodiments are defined in the dependent claims .
The present invention provides an antisense molecule binding to the mRNA of the protein PLAC8 for use as a medicament .
Antisense oligonucleotides ( or ASOs for short ) are synthetic, short-chain, single-stranded nucleic acids that are made up of a few nucleotides ( typically from 15 up to 30 nucleotides ) from a freely selectable sequence of bases . ASOs bind via complementary base pairing to a nucleic acid whose base sequence matches them ( opposite base pairs - " anti-sense" ) . In one embodiment, the antisense molecule is used for the treatment of diseases associated with an overexpression of PLAC8, for example cancer, like a pancreatic tumor, acute myeloide leukemia (AML) , cervical cancer, glioblastoma or renal clear cell carcinoma. The pancreatic tumor can be a pancreatic ductal adenocarcinoma (PDAC) or a pancreatic neuroendocrine tumor (PanNET) .
In one embodiment, the antisense molecule is an antisense oligonucleotide, which can have from 15 up to 30 nucleotides, in particular 15 to 20 nucleotides.
In another embodiment, the antisense molecule can be selected from the group consisting of siRNA, shRNA and GapmeRs . GapmeRs contain a central DNA region flanked on both sides with RNA regions. That is, the GapmeR can be represented in a simplified formula as RNA-DNA-RNA. That is, GapmeRs are DNA antisense structures with RNA-like segments on both sides of the sequence. These linear pieces of genetic information are designed to hybridize to a target piece of RNA (in the present case PLAC8) and silence the gene through the induction of cleavage. Binding of the GapmeRs to the target can have higher affinity due to modified RNA flanking regions, as well as resistance to degradation by nucleases.
Thus, in a further embodiment, the RNA regions can be chemically modified. For example, the chemical modification can be selected from the group consisting of 2'-0Me modified bases or 2'-F modified bases or a methylene bridge between the 2'-0 and the 4'-C-atom. GapmeRs having such a chemical modification of the RNA regions are known as LNA GapmeRs (LNA means locked nucleic acids) , wherein the RNA is locked in an ideal Watson-Crick pairing conformation due to the locking provided by the chemical modification. Antisense molecules used according to the present invention are known to the skilled person so that materials and methods for producing them are available . Furthermore , such antisense molecules are commercially available . For example , LNA Gampers can be purchased from Qiagen .
In a further embodiment , the antisense molecule can be used together with a so-called immune checkpoint inhibitor . This use can be carried out in that the checkpoint inhibitor is delivered before , together with or after the delivery of the antisense molecule .
According to the present invention, there is further provided the use of the antisense molecule as defined above for treating a disease associated with overexpression of PLAC8 as defined above as well .
A further subj ect-matter of the present invention is a method for treating a disease associated with overexpression of PLAC8 with an antisense molecule . For the details of such a method, in particular the antisense molecule and the diseases , it is referred to the above detailed description in its entirety .
Moreover, the present invention relates to a kit containing an antisense molecule directed against the mRNA of PLAC8 and instructions for use for treating a disease associated with PLAC8 overexpression .
In one embodiment , the kit further contains an immune checkpoint inhibitor .
PLAC8 is a gene encoding a small protein with unknown function . PLAC8 is practically absent in normal pancreatic tissue , but is regularly found highly overexpressed in PDAC as well as in other tumors . It has previously been shown that the PLAC8 gene , which codes for an evolutionarily highly conserved small protein of 115 AA, is strongly ectopically expressed in pancreatic ductal adenocarcinoma ( PDAC ) as well as a subset of pancreatic neuroendocrine tumors ( PanNET ) . Inhibition of PLAC8 expression signi ficantly impairs cell proli feration and viability in PDAC and PanNET cells .
One new aspect is that the functional entity mediating the cell-intrinsic pro-tumorigenic ef fects is not the PLAC8 protein, but the PLAC8 mRNA itsel f . To be more speci fic, it has been demonstrated through extensive experiments that , unexpectedly, it is not the protein, but the mRNA itsel f that is critical for tumor cell survival and proli feration, speci fically in a function within the nucleus itsel f (by default , mRNAs are transported out of the nucleus and translated into protein at ribosomes ) . Using commercially available antisense molecules ( ' LNA GapmeRs ' ; purchased from Qiagen GmbH) , it has been shown that targeted degradation of PLAC8 mRNA in the nucleus leads to massive DNA damage in the cell and, as a consequence , to complete inhibition of proli feration and ultimately cell death . Since LNA GapmeRs are in parts chemically modi fied DNA molecules , they are protected from degradation in the organism and can therefore also be used in vi vo .
Based on the above finding, it has therefore been concluded that targeting nuclear PLAC8 mRNA in tumor cells , e . g . , using nuclear antisense DNA molecules , would be a promising novel approach for pancreatic cancer therapy as well as other tumors . In this context , the ef fect of severe DNA damage is of particular interest as it is known from the literature that DNA damage contributes to the formation of ' neo-antigens ' , which make tumor cells visible to the immune system and can improve the effectiveness of so-called checkpoint inhibitor therapies, which have not yet shown efficacy in e.g. PDAC therapy. Moreover, the same principle could also be applied to other types of tumors which regularly show strong overexpression of PLAC8, such as acute myeloid leukemia (AML) , cervical cancer, glioblastoma, renal clear cell carcinoma etc.
The present invention will be further illustrated by the following examples and figures. It is explicitly pointed out that the examples shall not be construed to limit the invention thereto. The examples are only intended to illustrate the invention.
Figure 1 shows data about PLAC8.
Figure 2 shows the CRISPR/Cas9 targeting of PLAC8.
Figure 3 shows the genotype of S2-007-derived clone G2#l.
Figure 4 shows the pedigree of S2-007-derived clones.
Figure 5 shows the genomic organization and splice variants.
Figure 6 shows principles of function of the LNA-GapmeRs .
Figure 7 shows the GapmeRs effects in G2#l clone.
Figure 8 shows the effects of GapmeRs in G2#l clones.
Examples
Methods
Nanopore sequencing, CRISPR-mediated genome editing, LNA- GapmeR-mediated gene silencing, fluorescence microscopy, flow cytometry, FISH/chromosome painting, SNP array analyses Fig.l shows the previously known data relating to FLAG 8. The gene is located on chromosome 4 with 3-4 alleles per cell (S2 — 007 cell line) . The gene codes for a small protein (18 kDa) highly conserved in evolution. It is overexpressed in PDAC, which leads to enhanced cell proliferation so that it can be considered to be an oncogene.
As to Fig. 2, S2-007 clones with targeted inactivation of PLAC8 expression were generated using the CRISPR/Cas9 technology. The successful inactivation of all alleles should have abrogated protein and RNA expression completely (integration of an antibiotics resistance/ transcription stop cassette) . Clones devoid of PLAC8 protein were readily obtained, but grew as well as parental cells, and still reacted to PLAC8-specif ic siRNA transfection.
As shown in Fig. 3, the S2-007 clone is deprived of PLAC8 protein expression generated using the CRISPR/Cas9 technology. The usage of guide RNA 2 Clone G2#l was chosen for the CRISPR/Cas9 approach described in the following as this clone already had 2-3 incorporated transcription-stop cassettes at the PLAC8 gene locus and only one remaining "wt"-allele (with a frameshift caused by NHEJ) , which results in cells lacking the PLAC8 protein, but not the PLAC8 RNA.
The Clone G2#l derives from the S2-007 cell line and was created via a first round of CRISPR/Cas9 editing using a donor plasmid coding for a puromycin transcription-stop cassette. With regard to the genotype of clone G2#l it is already known that this clone has 3 integrated puromycin transcription-stop cassettes and 1 allele with a frameshift (4 NT-deletion) within exon 2 at the PLAC8 gene locus. This results in a gene KO at the protein, but not at the RNA level. Fig. 4 shows the pedigree of S2-007-derived clones. Second round of CRISPR/Cas9 editing in G2#l cells using a donor plasmid coding for a neomycin transcription-stop cassette and GuideRNA 1 is shown. The hypothetical genotype of these clones would consist of 3 integrated puromycin transcription-stop cassettes and 1 integrated neomycin transcription-stop cassette within exon 2 at the PLAC8 gene locus. This would result in a PLAC8-K0 at the protein and RNA level due to integrated transcriptional stop signals (polyA-signals ) into all of the four alleles at the PLAC8 gene locus.
However, the second round only yielded clones with additional indels, but not a single clone without RNA expression.
All in all, more than 250 clones were analyzed so far following different CRISPR/Cas-rounds ; no PLAC8 RNA-def icient clone was ever observed so that PLAC8 mRNA is relevant, not the protein.
Genomic organization of the PLAC8 gene locus on chromosome 4 and splice variants in pancreatic cancer cells as determined by Nanopore sequencing and RACE PGR (see Fig. 5) .
The principle of function of LNA-GapmeRs is represented in Fig. 6. Mechanism: Rnase H ubiquitous in almost all organisms for degradation of DNA- RNA- Hybrids (e.g. virus defence) GapmeR binds mRNA so that the degradation of the hybrid by RNaseH is achieved, which in turn results in complete degradation of the target mRNA within the cell nucleus.
GapmeR's in general have at least one of the following properties: They are antisense oligonucleotides (ASO, they are short (15-20 bases) single stranded nucleic acids. They have a central DNA "gap" (central DNA part) flanked by RNA pars on each side. They form DNA: RNA duplexes detected by RNaseH. Flanking regions contain " locked nucleic acids" ( LNA) which are nuclease resistant and have enhanced binding .
Fig . 7 shows individual/ independent GapmeRs elicited ef ficient knockdown of both, PLAC8 protein ( in parental cells ) and PLAC8 mRNA ( in PLAC8 protein-proficient as well as protein-deficient cell lines/clones ) . PLAC8 knockdown led to profound growth inhibition regardless of protein status , far surpassing ef ficacy of siRNAs .
As to Fig . 8 , it represents flow cytometry ( PI staining) showing slightly pronounced S-Phase , but BrdU assays demonstrated that cell proli feration was severely impaired after PLAC8 knockdown . Moreover, gamma-H2AX staining revealed induction on massive amounts of cell death, peaking 24h after trans fection of GapmeRs .
Results
CRISPR/Cas genome editing approaches aimed at complete abrogation of PLAC8 mRNA expression (homologous repair templates with transcription termination elements ) consistently failed to inactivate all PLAC8 alleles in cancer cells , even in repeat rounds using di f ferent selectable markers . Clones deficient in producing the PLAC8 protein, however, were readily obtained ( random indel mutations disrupting the PLAC8 ORF following non-homologous end j oining) . Moreover, PLAC8 protein-deficient clones showed no di f ferences in growth rates compared to parental cell lines , but strongly reacted to PLAC8 mRNA knockdown, in particular to LNA GapmeR-mediated knockdown of nuclear-located PLAC8 mRNA, with induction of massive DNA damage and growth inhibition . Nanopore sequencing identi fied several novel PLAC8 splice isoforms , but recombinant expression of none of these isoforms was able to rescue the knockdown phenotype . Conclusion
The results imply that the PLAC8 mRNA i ) functions similarly to a cis-acting long non-coding RNA; ii ) has an important and non-redundant role in maintaining genomic integrity in pancreas cancer cells ; and ill ) functions completely independently of the encoded protein . Both aspects ( separate functions of mRNA and encoded protein, and a central role of an mRNA in maintaining genome stability) have not previously been described in any cellular context .

Claims

Claims
1. Antisense molecule binding to the mRNA of the protein PLAC8 for use as a medicament.
2. Antisense molecule according to claim 1 for use in the treatment of diseases associated with an overexpression of PLAC8.
3. Antisense molecule according to claim 2, wherein the disease associated with the overexpression of PLAC8 is cancer.
4. Antisense molecule according to claim 3, wherein the cancer is a pancreatic tumor, acute myeloide leukemia (AML) , cervical cancer, glioblastoma or renal clear cell carcinoma.
5. Antisense molecule according to claim 4, wherein the pancreatic tumor is pancreatic ductal adenocarcinoma (PDAC) or pancreatic neuroendocrina tumor (PanNET) .
6. Antisense molecule according to any of the preceding claims, wherein the antisense molecule is an antisense oligonucleotide .
7. Antisense molecule according to claim 6, wherein the oligonucleotide has 15 to 30 nucleotides.
8. Antisense molecule according to claim 6 or 7, wherein the antisense molecule is selected from the group consisting of siRNA, shRNA and GapmeRs .
9. Antisense molecule according to claim 8, wherein the RNA regions are chemically modified.
10. Antisense molecule according to claim 9, wherein the chemical modification is selected from the group consisting of 2'-OMe modified bases, 2'-F modified bases and a methylene bridge between the 2'-0 and the 4'-C-atom.
11. Antisense molecule according to any of the preceding claims, wherein further an immune checkpoint inhibitor is used .
12. Use of the antisense molecule as defined in any of claims 1 and 6 to 10 for treating a disease associated with an overexpression of PLAC8 as defined in any of claims 1 to 5.
13. Method for treating a disease associated with an overexpression of PLAC8 with an antisense molecule.
14. Kit containing an antisense molecule directed against the mRNA of PLAC8 and instructions for use for treating a disease associated with an PLAC8 overexpression.
15. Kit according to claim 1 further containing a checkpoint inhibitor .
EP24706690.5A 2023-03-01 2024-02-19 Plac8 antisense molecules used as a medicament Pending EP4673542A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23159355 2023-03-01
PCT/EP2024/054144 WO2024179870A1 (en) 2023-03-01 2024-02-19 Plac8 antisense molecules used as a medicament

Publications (1)

Publication Number Publication Date
EP4673542A1 true EP4673542A1 (en) 2026-01-07

Family

ID=85415392

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24706690.5A Pending EP4673542A1 (en) 2023-03-01 2024-02-19 Plac8 antisense molecules used as a medicament

Country Status (2)

Country Link
EP (1) EP4673542A1 (en)
WO (1) WO2024179870A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008307544A1 (en) * 2007-10-02 2009-04-09 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
CA3125285A1 (en) * 2018-12-27 2020-07-02 Sirnaomics, Inc. Silencing tgf-beta 1 and cox2 using sirnas delivered in combination with immune checkpoint inhibitors to treat cancer

Also Published As

Publication number Publication date
WO2024179870A1 (en) 2024-09-06

Similar Documents

Publication Publication Date Title
US20230348908A1 (en) RNA Interactome of Polycomb Repressive Complex 1 (PRC1)
JP7406278B2 (en) Long non-coding RNA LETN as a tumor marker and therapeutic target
Brysch et al. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents
CN113817823B (en) Long non-coding RNA LETN as a tumor marker and therapeutic target
EP3230453B1 (en) Downregulating mir-132 for the treatment of lipid related disorders
US20160024597A1 (en) miRNAs AS THERAPEUTIC TARGETS IN CANCER
KR101052289B1 (en) Treatment of melanoma with a decrease in the amount of cholesterol
CN117568347B (en) Application of PPEF1 as neuroblastoma drug target
Maksimenko et al. Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma
WO2008099396A1 (en) Use of h19-silencing nucleic acid agents for treating restenosis
JP2022541212A (en) SiRNA sequences targeting the expression of the human genes JAK1 or JAK3 for therapeutic use
WO2024179870A1 (en) Plac8 antisense molecules used as a medicament
EP2336320B1 (en) Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
Fluiter et al. Killing cancer by targeting genes that cancer cells have lost: allele-specific inhibition, a novel approach to the treatment of genetic disorders
CN108245527B (en) Method and medicine for resisting cancer through miR-1181 and application thereof
Pérez et al. MicroRNA interference
Prins et al. Antisense of oligonucleotides and the inhibition of oncogene expression
KR20200069185A (en) nc886 and/or PKR inhibitors as ancillary agents for anti-cancer drugs and methods to provide improved regimens for them
US11357853B2 (en) Inhibition of a lncRNA for treatment of neuroblastoma
JP7454207B2 (en) Pancreatic cancer cell invasion and metastasis inhibitor
WO2012131673A2 (en) Ccat-1 silencing nucleic acid agents for treating cancer
KR20210074227A (en) Guide RNA for deleting MYC enhancer and use thereof
KR20240034143A (en) Novel genomic safe harbor and the use thereof
CN121109382A (en) Oligonucleotides that regulate alternative splicing of the SLK gene, their preparation and applications
WO2019246571A1 (en) Compositions and methods for treating adrenocortical carcinoma

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250813

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR